微创胰十二指肠切除术:对衰弱胰腺癌患者的一种有利方法
本研究利用美国外科医师学会国家外科质量改进计划胰腺切除术数据库(2014-2021),比较衰弱胰腺导管腺癌患者行开放与微创胰十二指肠切除术的30天术后结局。共识别3143例衰弱患者,其中275例(9%)接受微创手术。微创组任何并发症(43% vs 54%;P < .001)、重大并发症(29% vs 35%;P = .042)和非家庭出院(12% vs 17%;P = .022)均低于开放组。机器人手术较腹腔镜并发症更少(39% vs 51%;P = .040)且死亡率更低(1% vs 4%;P = .041)。
要点
- 衰弱胰腺癌患者中,微创胰十二指肠切除术较开放手术任何并发症更低(43% vs 54%;P < .001)。
- 微创组重大并发症(29% vs 35%;P = .042)和非家庭出院(12% vs 17%;P = .022)均低于开放组。
- 机器人较腹腔镜并发症更少(39% vs 51%;P = .040)且死亡率更低(1% vs 4%;P = .041)。
核心结论
- 在衰弱胰腺癌患者中,微创胰十二指肠切除术与开放胰十二指肠切除术相比,术后结局更好。
研究设计与样本
- 使用美国外科医师学会国家外科质量改进计划胰腺切除术靶向数据库(2014-2021)识别胰腺导管腺癌胰十二指肠切除术病例。
- 改良衰弱指数≥2的患者被定义为衰弱。
- 对开放与微创胰十二指肠切除术按2:1进行最优配对倾向性评分匹配,匹配患者和疾病特征。
主要发现
- 共识别3143例因胰腺导管腺癌行胰十二指肠切除术的衰弱患者,其中275例(9%)接受微创胰十二指肠切除术。
- 微创组任何并发症发生率为43%,开放组为54%(P < .001)。
- 微创组重大并发症发生率为29%,开放组为35%(P = .042)。
- 微创组非家庭出院率为12%,开放组为17%(P = .022)。
- 机器人手术并发症发生率为39%,腹腔镜为51%(P = .040);机器人手术死亡率为1%,腹腔镜为4%(P = .041)。
临床怎么用
- 鉴于衰弱患者并发症风险特别高,实施术前衰弱评估可为患者咨询提供有价值的信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Within the past decade, minimally invasive pancreaticoduodenectomy has been increasingly adopted in high-volume cancer centers. Amid broader trends of a growing older population, the numbers of frail patients with cancer are expected to increase. In this study, we compared the postoperative outcomes of open pancreaticoduodenectomy and minimally invasive pancreaticoduodenectomy in frail patients with pancreatic ductal adenocarcinoma. METHODS: Using the pancreatectomy-targeted American College of Surgeons-National Surgical Quality Improvement Program database (2014-2021), we identified pancreaticoduodenectomy cases for pancreatic ductal adenocarcinoma. Patients with a modified frailty index ≥2 were considered frail. We performed 2:1 (open pancreaticoduodenectomy to minimally invasive pancreaticoduodenectomy) optimal pair propensity score matching for both patient- and disease-specific characteristics. We evaluated baseline covariate balance for homogeneity and assessed 30-day postoperative outcomes: complications, discharge destination, major morbidity, and mortality. RESULTS: We identified 3,143 frail patients who underwent pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Of those, 275 (9%) underwent minimally invasive pancreaticoduodenectomy. Minimally invasive pancreaticoduodenectomy was associated with a lower rate of any complications compared with open pancreaticoduodenectomy (43% vs 54%; P < .001), major morbidity (29% vs 35%; P = .042), and nonhome discharge (12% vs 17%; P = .022). When comparing the 2 minimally invasive pancreaticoduodenectomy approaches, robotic surgery was associated with fewer complications compared with laparoscopy (39% vs 51%; P = .040) and a lower mortality rate (1% vs 4%; P = .041) CONCLUSION: In frail patients with pancreatic cancer, minimally invasive pancreaticoduodenectomy was associated with better postoperative outcomes than open pancreaticoduodenectomy. This study builds on growing literature reporting that, when properly implemented, minimally invasive pancreaticoduodenectomy is associated with more favorable postoperative outcomes. Given the particularly high risk of complication in frail patients, implementing a preoperative frailty assessment can provide valuable insights to inform patient counseling.
引用
- Farah E, Al Abbas A, Abreu AA, et al. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Surgery. 2024. PMID: 38307784. doi:10.1016/j.surg.2023.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。